LivingGLP1
Study S002028

A Human Laboratory Study of Exenatide for Reducing the Reinforcing Effects of Cocaine

ClinicalTrials.gov record

Registration

Registration
NCT06252623
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1
Masking
QUADRUPLE
Status
WITHDRAWN
Enrollment
0
Start
2024-08-01
Primary completion
2026-03-01
Lead sponsor
Christopher D. Verrico
Conditions
Cocaine Use Disorder
Interventions
DRUG:Exenatide; DRUG:Placebo
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Proportion of up to 10 active cocaine doses [6 weeks]
  • Subjective Effects [6 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.